Abstract:Background Developing innovative drugs with potent efficacy, specificity, and high safety remains an ongoing task in antitumor therapy development. In the last few years, peptide drugs have become attractive agents in cancer therapy. HM-3, mainly with antiangiogenic effect, and AP25, with an additional antiproliferative effect, are two peptides designed in our laboratory targeting αvβ3 and α5β1 integrins, respectively. The low molecular weight of the two peptides renders their recombinant expression very difficult, and the complicated structure of AP25 makes its chemical synthesis restricted, which presents a big challenge for its development. Methods Bifunctional peptides designed by the ligation of HM-3 and AP25, using linkers with different flexibility, were prepared using recombinant DNA technology in Escherichia coli. The fusion peptides were expressed in a modified auto-induction medium based on a mixture of glucose, glycerol, and lactose as carbon substrates and NH4+ as nitrogen source without any amino acid or other elements. Subsequently, the antiangiogenic, antiproliferative, and cell adhesion assays were conducted to evaluate the bioactivity of the two fusion peptides. Results The peptides were successfully expressed in a soluble form without any induction, which allows the culture to reach higher cell density before protein expression occurs. Human umbilical vein endothelial cell migration assay and chick embryo chorioallantoic membrane assay showed, at low doses, a significantly increased antiangiogenic effect (>75%) of the purified products compared with the single molecules. Meanwhile, MTT assay confirmed their enhanced antitumor activity against gastric cancer cell line MGC-803; however, no significant effect was observed on hepatoma HepG2 cells and no cytotoxicity on normal human lens epithelial cell SRA01/04 and human epithelial esophageal cells. Conclusion Bifunctional molecules with antiangiogenic and antiproliferative effects were obtained by using this technique, which presents an alternative for small peptide production, instead of the conventional chemical method. The increased molecular weight facilitates the peptide expression with a simultaneous improvement in their stability and biological activity.

An Investigation on a Novel Anti-tumor Fusion Peptide of FSH33-53-IIKK.

Rational design of an EGF-IL18 fusion protein: implication for developing tumor therapeutics.

Enhanced EPR Effects by Tumour Stromal Cell Mimicking Nanoplatform on Invasive Pituitary Adenoma

A New Fusion Peptide Targeting Pancreatic Cancer and Inhibiting Tumor Growth.

Development of a novel albumin-based and maleimidopropionic acid-conjugated peptide with prolonged half-life and increased in vivo anti-tumor efficacy

[Inhibition of tumor growth by a peptide fusion protein binding to vascular endothelial growth factor receptor Flt-1]

A Novel Trichosanthin Fusion Protein with Increased Cytotoxicity to Tumor Cells

Tumor Targeting and Microenvironment-Responsive Multifunctional Fusion Protein for Pro-Apoptotic Peptide Delivery

A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors

THE STUDY OF EXPRESSION AND FUNCTION OF ANTIBODY-CYTOKINE FUSION PROTEIN 183B2scfv-Interleukin 2

Efficient Growth Inhibition of ErbB2-overexpressing Tumor Cells by Antierbb2 ScFv-Fc-IL-2 Fusion Protein in Vitro and in Vivo

Tumor-Targeted Delivery of IL-2 by Fusing with a pH Low Insertion Peptide for Antitumor Immunotherapy

Targeting Matrix Metalloproteinases And Endothelial Cells With A Fusion Peptide Against Tumor

Novel Production Method of Innovative Antiangiogenic and Antitumor Small Peptides in Escherichia Coli

A novel PD-L1 targeting peptide self-assembled nanofibers for sensitive tumor imaging and photothermal immunotherapy in vivo

A Targeted IL-15 Fusion Protein with Potent Anti-Tumor Activity.

Small peptides elicit anti-tumor effects in CT26 model through blocking PD-L1/PD-1 (TUM2P.900)

Anti-Tumor Activity and Pharmacokinetics of AP25-Fc Fusion Protein

Screening a novel FGF3 antagonist peptide with anti-tumor effects on breast cancer from a phage display library

A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities

In Silico Exploration and Biological Evaluation of Bispecific Peptides Derived from Anti-HER2 Antibodies and Peptide-Camptothecin Conjugates for HER2-Positive Breast Cancer